Insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Bio-techne Corp (TECH) since 2015 are shown in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Bio-techne Corp. Table 2 shows the detailed insider transactions. This company's CIK number is 842023.
Total stock buying since 2015: $238,295.
Total stock sales since 2015: $211,729,965.
Total stock option exercises since 2015: $128,315,732.
| Insider Buying | Insider Sales | Option Exercises | ||||
|---|---|---|---|---|---|---|
| Year | Shares | Value | Shares | Value | Shares | Value |
| 2025 | 0 | $0 | 35,360 | $1,981,913 | 471,926 | $18,792,422 |
| 2024 | 0 | $0 | 30,400 | $2,289,663 | 160,871 | $4,112,999 |
| 2023 | 0 | $0 | 89,261 | $7,813,728 | 804,149 | $19,079,029 |
| 2022 | 300 | $105,765 | 6,704 | $2,446,923 | 131,527 | $11,605,770 |
| 2021 | 0 | $0 | 212,603 | $93,545,992 | 338,115 | $32,814,686 |
| 2020 | 0 | $0 | 203,677 | $54,137,437 | 277,437 | $22,579,574 |
| 2019 | 700 | $132,530 | 177,870 | $37,927,611 | 224,333 | $14,460,601 |
| 2018 | 0 | $0 | 34,136 | $5,831,411 | 43,372 | $1,560,600 |
| 2017 | 0 | $0 | 18,118 | $2,120,290 | 25,915 | $981,050 |
| 2016 | 0 | $0 | 19,724 | $1,996,586 | 21,666 | $1,293,414 |
| 2015 | 0 | $0 | 16,000 | $1,638,411 | 20,218 | $1,035,587 |
| Trading Period | Insider Buying | Insider Sales | Option Exercises | |||
|---|---|---|---|---|---|---|
| year-month | Shares | Value | Shares | Value | Shares | Value |
| 2025-08 | 0 | $0 | 34,080 | $1,918,209 | 58,930 | $854,379 |
| 2025-07 | 0 | $0 | 0 | $0 | 397,456 | $17,619,221 |
| 2025-06 | 0 | $0 | 1,280 | $63,704 | 1,280 | $56,742 |
| 2025-05 | 0 | $0 | 0 | $0 | 12,000 | $262,080 |
| 2025-04 | 0 | $0 | 0 | $0 | 2,260 | $0 |
| 2024-11 | 0 | $0 | 0 | $0 | 23,071 | $0 |
| 2024-09 | 0 | $0 | 0 | $0 | 6,000 | $137,700 |
| 2024-08 | 0 | $0 | 16,000 | $1,153,664 | 70,541 | $2,123,899 |
| 2024-07 | 0 | $0 | 0 | $0 | 55,000 | $1,759,600 |
| 2024-05 | 0 | $0 | 4,000 | $335,376 | 4,000 | $91,800 |
| 2024-04 | 0 | $0 | 0 | $0 | 2,259 | $0 |
| 2024-03 | 0 | $0 | 10,400 | $800,623 | 0 | $0 |
| 2023-12 | 0 | $0 | 0 | $0 | 47,289 | $1,478,254 |
| 2023-08 | 0 | $0 | 8,939 | $717,962 | 124,184 | $816,760 |
| 2023-07 | 0 | $0 | 80,000 | $7,069,040 | 0 | $0 |
| 2023-06 | 0 | $0 | 322 | $26,726 | 616,676 | $16,434,415 |
| 2023-04 | 0 | $0 | 0 | $0 | 16,000 | $349,600 |
| 2022-08 | 0 | $0 | 0 | $0 | 25,751 | $99,831 |
| 2022-07 | 0 | $0 | 0 | $0 | 95,346 | $10,344,087 |
| 2022-06 | 0 | $0 | 6,704 | $2,446,923 | 6,704 | $660,772 |
| 2022-05 | 300 | $105,765 | 0 | $0 | 0 | $0 |
| 2022-02 | 0 | $0 | 0 | $0 | 1,989 | $299,901 |
| 2022-01 | 0 | $0 | 0 | $0 | 1,737 | $201,179 |
| 2021-11 | 0 | $0 | 36,681 | $18,704,592 | 37,480 | $4,699,737 |
| Trade Date | Insider Name | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2025-08-25 | Nusse Roeland (Director) | Sale | 17,040 | 56.36 | 960,391 |
| 2025-08-25 | Nusse Roeland (Director) | Option Ex | 17,040 | 21.84 | 372,153 |
| 2025-08-25 | Baumgartner Robert V (Director) | Sale | 17,040 | 56.21 | 957,818 |
| 2025-08-25 | Baumgartner Robert V (Director) | Option Ex | 17,040 | 21.84 | 372,153 |
| 2025-08-15 | Herr Amy E. (Director) | Option Ex | 279 | .00 | 0 |
| 2025-08-15 | Bohnen Shane (SVP - General Counsel) | Option Ex | 1,718 | .00 | 0 |
| 2025-08-15 | Mcmanus Matthew (President - Diag & Spatial Bio) | Option Ex | 2,637 | .00 | 0 |
| 2025-08-15 | Geist William (PRESIDENT, PROTEIN SCIENCES) | Option Ex | 2,623 | .00 | 0 |
| 2025-08-15 | Kelderman Kim (Chief Executive Officer) | Option Ex | 8,543 | .00 | 0 |
| 2025-08-15 | Hippel James (CFO) | Option Ex | 4,010 | .00 | 0 |
| 2025-08-07 | Higgins John L (Director) | Option Ex | 5,040 | 21.84 | 110,073 |
| 2025-07-29 | Hippel James (CFO) | Option Ex | 168,620 | 44.33 | 7,474,924 |
| 2025-07-22 | Kelderman Kim (Chief Executive Officer) | Option Ex | 48,176 | 44.33 | 2,135,642 |
| 2025-07-15 | Kelderman Kim (Chief Executive Officer) | Option Ex | 108,396 | 44.33 | 4,805,193 |
| 2025-06-09 | Herr Amy E. (Director) | Sale | 1,280 | 49.77 | 63,704 |
| 2025-06-09 | Herr Amy E. (Director) | Option Ex | 1,280 | 44.33 | 56,742 |
| 2025-05-01 | Higgins John L (Director) | Option Ex | 12,000 | 21.84 | 262,080 |
| 2025-04-03 | Bohnen Shane (SVP - General Counsel) | Option Ex | 2,260 | .00 | 0 |
| 2024-11-01 | Geist William (PRESIDENT, PROTEIN SCIENCES) | Option Ex | 9,912 | .00 | 0 |
| 2024-11-01 | Hippel James (CFO) | Option Ex | 13,159 | .00 | 0 |
| 2024-09-12 | Higgins John L (Director) | Option Ex | 6,000 | 22.95 | 137,700 |
| 2024-08-29 | Kelderman Kim (Chief Executive Officer) | Option Ex | 1,492 | 66.97 | 99,919 |
| 2024-08-15 | Bohnen Shane (SVP - General Counsel) | Option Ex | 49 | .00 | 0 |
| 2024-08-08 | Baumgartner Robert V (Director) | Sale | 16,000 | 72.10 | 1,153,664 |
| 2024-08-08 | Baumgartner Robert V (Director) | Option Ex | 16,000 | 22.95 | 367,200 |
| 2024-08-02 | Hippel James (CFO) | Option Ex | 53,000 | 31.26 | 1,656,780 |
| 2024-07-31 | Kelderman Kim (Chief Executive Officer) | Option Ex | 14,000 | 37.70 | 527,800 |
| 2024-07-23 | Hippel James (CFO) | Option Ex | 35,000 | 31.26 | 1,094,100 |
| 2024-07-08 | Higgins John L (Director) | Option Ex | 6,000 | 22.95 | 137,700 |
| 2024-05-14 | Higgins John L (Director) | Sale | 4,000 | 83.84 | 335,376 |
| 2024-05-14 | Higgins John L (Director) | Option Ex | 4,000 | 22.95 | 91,800 |
| 2024-04-03 | Bohnen Shane (SVP - General Counsel) | Option Ex | 2,259 | .00 | 0 |
| 2024-03-07 | Nusse Roeland (Director) | Sale | 10,400 | 76.98 | 800,623 |
| 2023-12-19 | Hippel James (CFO) | Option Ex | 47,289 | 31.26 | 1,478,254 |
| 2023-08-30 | Nusse Roeland (Director) | Sale | 8,939 | 80.32 | 717,962 |
| 2023-08-30 | Nusse Roeland (Director) | Option Ex | 32,000 | 22.40 | 716,800 |
| 2023-08-24 | Kelderman Kim (Pres. Diagnostics & Genom) | Option Ex | 2,100 | 47.60 | 99,960 |
| 2023-08-15 | Kummeth Charles R. (Chief Executive Officer) | Option Ex | 17,632 | .00 | 0 |
| 2023-08-05 | Kelderman Kim (Pres. Diagnostics & Genom) | Option Ex | 8,060 | .00 | 0 |
| 2023-08-05 | Hippel James (CFO) | Option Ex | 12,876 | .00 | 0 |
| 2023-08-05 | Kummeth Charles R. (Chief Executive Officer) | Option Ex | 51,516 | .00 | 0 |
| 2023-07-21 | Kummeth Charles R. (Chief Executive Officer) | Sale | 80,000 | 88.36 | 7,069,040 |
| 2023-06-30 | Kummeth Charles R. (Chief Executive Officer) | Option Ex | 616,676 | 26.65 | 16,434,415 |
| 2023-06-07 | Kummeth Charles R. (Chief Executive Officer) | Sale | 322 | 83.00 | 26,726 |
| 2023-04-28 | Higgins John L (Director) | Option Ex | 16,000 | 21.85 | 349,600 |
| 2022-08-08 | Furlow Brenda S. (SVP - General Counsel) | Option Ex | 563 | 177.32 | 99,831 |
| 2022-08-07 | Kelderman Kim (Pres. Diagnostics & Genom) | Option Ex | 2,363 | .00 | 0 |
| 2022-08-07 | Hippel James (Chief Financial Officer) | Option Ex | 3,938 | .00 | 0 |
| 2022-08-07 | Kummeth Charles R. (Chief Executive Officer) | Option Ex | 16,918 | .00 | 0 |
| 2022-08-07 | Furlow Brenda S. (SVP - General Counsel) | Option Ex | 1,969 | .00 | 0 |
| 2022-07-28 | Kummeth Charles R. (CHIEF EXECUTIVE OFFICER) | Option Ex | 45,346 | 108.49 | 4,919,587 |
| 2022-07-06 | Kummeth Charles R. (CHIEF EXECUTIVE OFFICER) | Option Ex | 50,000 | 108.49 | 5,424,500 |
| 2022-06-08 | Higgins John L | Sale | 600 | 366.09 | 219,653 |
| 2022-06-08 | Higgins John L | Option Ex | 600 | 66.90 | 40,140 |
| 2022-06-07 | Kummeth Charles R. (CHIEF EXECUTIVE OFFICER) | Sale | 5,104 | 365.00 | 1,862,960 |
| 2022-06-07 | Kummeth Charles R. (CHIEF EXECUTIVE OFFICER) | Option Ex | 5,104 | 108.49 | 553,732 |
| 2022-06-07 | Higgins John L | Sale | 1,000 | 364.31 | 364,310 |
| 2022-06-07 | Higgins John L | Option Ex | 1,000 | 66.90 | 66,900 |
| 2022-05-10 | Baumgartner Robert V | Buy | 300 | 352.55 | 105,765 |
| 2022-02-08 | Kelderman Kim (Pres. Diagnostics & Genom) | Option Ex | 1,989 | 150.78 | 299,901 |
| 2022-01-28 | Kummeth Charles R. (Chief Executive Officer) | Option Ex | 1,737 | 115.82 | 201,179 |
| 2021-11-19 | Kelderman Kim (Pres. Diagnostics & Genom) | Sale | 500 | 504.77 | 252,385 |
| 2021-11-19 | Kelderman Kim (Pres. Diagnostics & Genom) | Option Ex | 500 | 150.78 | 75,390 |
| 2021-11-16 | Eansor Norman David (President-Protein Sciences) | Option Ex | 799 | 125.05 | 99,914 |
| 2021-11-12 | Eansor Norman David (President-Protein Sciences) | Sale | 27,159 | 504.35 | 13,697,641 |
| 2021-11-12 | Eansor Norman David (President-Protein Sciences) | Option Ex | 27,159 | 125.05 | 3,396,232 |
| 2021-11-02 | Hippel James (Chief Financial Officer) | Sale | 200 | 525.10 | 105,020 |
| 2021-11-02 | Hippel James (Chief Financial Officer) | Option Ex | 200 | 125.05 | 25,010 |
| 2021-11-01 | Hippel James (Chief Financial Officer) | Sale | 8,822 | 527.04 | 4,649,546 |
| 2021-11-01 | Hippel James (Chief Financial Officer) | Option Ex | 8,822 | 125.05 | 1,103,191 |
| 2021-10-29 | Hippel James (Chief Financial Officer) | Sale | 662 | 525.23 | 347,704 |
| 2021-10-29 | Hippel James (Chief Financial Officer) | Option Ex | 662 | 125.05 | 82,783 |
| 2021-10-28 | Hippel James (Chief Financial Officer) | Sale | 100 | 525.18 | 52,517 |
| 2021-09-22 | Kelderman Kim (Pres. Diagnostics & Genom) | Sale | 822 | 529.04 | 434,870 |
| 2021-09-07 | Steer Randolph C | Sale | 8,000 | 510.33 | 4,082,680 |
| 2021-09-07 | Steer Randolph C | Option Ex | 8,000 | 89.58 | 716,680 |
| 2021-09-02 | Hippel James (Chief Financial Officer) | Sale | 10,000 | 508.19 | 5,081,930 |
| 2021-09-02 | Hippel James (Chief Financial Officer) | Option Ex | 10,000 | 106.59 | 1,065,900 |
| 2021-09-02 | Kummeth Charles R. (Chief Executive Officer) | Option Ex | 73,492 | 108.49 | 7,973,147 |
| 2021-09-02 | Furlow Brenda S. (SVP - General Counsel) | Sale | 6,871 | 510.25 | 3,505,900 |
| 2021-09-02 | Furlow Brenda S. (SVP - General Counsel) | Option Ex | 6,871 | 125.05 | 859,218 |
| 2021-08-31 | Furlow Brenda S. (SVP - General Counsel) | Sale | 5,000 | 504.87 | 2,524,360 |
| 2021-08-31 | Furlow Brenda S. (SVP - General Counsel) | Option Ex | 5,000 | 125.05 | 625,250 |
| 2021-08-31 | Eansor Norman David (President-Protein Sciences) | Sale | 1,538 | 503.07 | 773,727 |
| 2021-08-23 | Nusse Roeland | Sale | 4,000 | 481.52 | 1,926,064 |
| 2021-08-23 | Nusse Roeland | Option Ex | 4,000 | 70.35 | 281,400 |
| 2021-08-23 | Baumgartner Robert V | Sale | 4,000 | 485.27 | 1,941,092 |
| 2021-08-23 | Baumgartner Robert V | Option Ex | 4,000 | 87.39 | 349,560 |
| 2021-08-19 | Furlow Brenda S. (SVP - General Counsel) | Sale | 3,538 | 474.08 | 1,677,309 |
| 2021-08-19 | Furlow Brenda S. (SVP - General Counsel) | Option Ex | 4,337 | 115.82 | 502,311 |
| 2021-08-11 | Kummeth Charles R. (Chief Executive Officer) | Option Ex | 921 | 108.49 | 99,919 |
| 2021-08-09 | Hippel James (Chief Financial Officer) | Sale | 10,000 | 480.98 | 4,809,750 |
| 2021-08-09 | Hippel James (Chief Financial Officer) | Option Ex | 10,000 | 106.59 | 1,065,900 |
| 2021-08-08 | Kelderman Kim (Pres. Diagnostics & Genom) | Option Ex | 1,691 | .00 | 0 |
| 2021-08-08 | Hippel James (Chief Financial Officer) | Option Ex | 3,383 | .00 | 0 |
| 2021-08-08 | Furlow Brenda S. (SVP - General Counsel) | Option Ex | 1,374 | .00 | 0 |
| 2021-08-08 | Eansor Norman David (President-Protein Sciences) | Option Ex | 2,537 | .00 | 0 |
| 2021-08-06 | Kummeth Charles R. (Chief Executive Officer) | Option Ex | 16,918 | .00 | 0 |
| 2021-07-12 | Hippel James (Chief Financial Officer) | Sale | 10,000 | 457.80 | 4,577,990 |
| 2021-07-12 | Hippel James (Chief Financial Officer) | Option Ex | 10,000 | 106.59 | 1,065,900 |
| 2021-06-18 | Kummeth Charles R. (Chief Executive Officer) | Sale | 2,909 | 449.73 | 1,308,264 |
| 2021-06-17 | Kummeth Charles R. (Chief Executive Officer) | Sale | 9,589 | 450.85 | 4,323,219 |
| 2021-06-14 | Kummeth Charles R. (Chief Executive Officer) | Sale | 7,481 | 449.60 | 3,363,457 |
| 2021-06-09 | Kelderman Kim (Pres. Diagnostics & Genom) | Sale | 811 | 433.00 | 351,163 |
| 2021-05-25 | Kelderman Kim (Pres. Diagnostics & Genom) | Sale | 845 | 424.00 | 358,280 |
| 2021-05-25 | Kummeth Charles R. (Chief Executive Officer) | Option Ex | 36,849 | 94.35 | 3,476,703 |
| 2021-05-01 | Kelderman Kim (Pres. Diagnostics & Genom) | Option Ex | 1,667 | .00 | 0 |
| 2021-02-16 | Kummeth Charles R. (Chief Executive Officer) | Option Ex | 30,000 | 94.35 | 2,830,500 |
| 2021-02-12 | Hippel James (Chief Financial Officer) | Sale | 10,000 | 400.92 | 4,009,180 |
| 2021-02-12 | Hippel James (Chief Financial Officer) | Option Ex | 10,000 | 106.59 | 1,065,900 |
| 2021-02-12 | Furlow Brenda S. (SVP - General Counsel) | Sale | 10,000 | 398.76 | 3,987,559 |
| 2021-02-12 | Furlow Brenda S. (SVP - General Counsel) | Option Ex | 10,000 | 106.59 | 1,065,900 |
| 2021-02-08 | Nusse Roeland | Sale | 6,000 | 385.08 | 2,310,480 |
| 2021-02-08 | Nusse Roeland | Option Ex | 6,000 | 68.62 | 411,750 |
| 2021-02-05 | Kelderman Kim (Pres. Diagnostics & Genom) | Sale | 823 | 388.45 | 319,694 |
| 2021-02-05 | Eansor Norman David (President-Protein Sciences) | Sale | 32,933 | 381.75 | 12,572,271 |
| 2021-02-05 | Eansor Norman David (President-Protein Sciences) | Option Ex | 32,933 | 106.59 | 3,510,328 |
| 2021-01-15 | Kummeth Charles R. (Chief Executive Officer) | Sale | 20,000 | 344.00 | 6,880,000 |
| 2021-01-11 | Hippel James (Chief Financial Officer) | Sale | 10,000 | 332.19 | 3,321,940 |
| 2021-01-11 | Hippel James (Chief Financial Officer) | Option Ex | 10,000 | 106.59 | 1,065,900 |
| 2020-12-07 | Kummeth Charles R. (Chief Executive Officer) | Sale | 5,000 | 308.00 | 1,540,000 |
| 2020-11-30 | Furlow Brenda S. (SVP - General Counsel) | Sale | 10,857 | 302.10 | 3,279,867 |
| 2020-11-30 | Furlow Brenda S. (SVP - General Counsel) | Option Ex | 11,795 | 106.59 | 1,257,229 |
| 2020-11-18 | Baumgartner Robert V | Sale | 5,000 | 303.33 | 1,516,675 |
| 2020-11-18 | Baumgartner Robert V | Option Ex | 5,000 | 66.90 | 334,500 |
| 2020-11-11 | Hippel James (Chief Financial Officer) | Sale | 7,391 | 307.35 | 2,271,638 |
| 2020-11-11 | Hippel James (Chief Financial Officer) | Option Ex | 7,391 | 106.59 | 787,806 |
| 2020-11-09 | Seth Alpna | Sale | 5,023 | 306.35 | 1,538,770 |
| 2020-11-09 | Seth Alpna | Option Ex | 5,023 | 152.44 | 765,731 |
| 2020-11-09 | Hippel James (Chief Financial Officer) | Sale | 3,600 | 309.86 | 1,115,485 |
| 2020-11-09 | Hippel James (Chief Financial Officer) | Option Ex | 3,600 | 106.59 | 383,724 |
| 2020-11-06 | Kummeth Charles R. (Chief Executive Officer) | Option Ex | 25,157 | 86.25 | 2,169,791 |
| 2020-11-06 | Higgins John L | Sale | 5,000 | 299.96 | 1,499,800 |
| 2020-11-06 | Higgins John L | Option Ex | 5,000 | 70.35 | 351,750 |
| 2020-11-06 | Steer Randolph C | Sale | 10,000 | 301.97 | 3,019,730 |
| 2020-11-06 | Steer Randolph C | Option Ex | 10,000 | 68.62 | 686,250 |
| 2020-11-05 | Hippel James (Chief Financial Officer) | Sale | 8,809 | 286.21 | 2,521,197 |
| 2020-11-05 | Hippel James (Chief Financial Officer) | Option Ex | 8,809 | 108.49 | 955,688 |
| 2020-11-04 | Hippel James (Chief Financial Officer) | Sale | 7,100 | 274.17 | 1,946,614 |
| 2020-11-04 | Hippel James (Chief Financial Officer) | Option Ex | 7,100 | 108.49 | 770,279 |
| 2020-08-09 | Hippel James (Chief Financial Officer) | Option Ex | 4,438 | .00 | 0 |
| 2020-08-09 | Kummeth Charles R. (Chief Executive Officer) | Option Ex | 21,291 | .00 | 0 |
| 2020-08-09 | Furlow Brenda S. (SVP - General Counsel) | Option Ex | 1,724 | .00 | 0 |
| 2020-08-09 | Eansor Norman David (President-Protein Sciences) | Option Ex | 2,174 | .00 | 0 |
| 2020-07-09 | Furlow Brenda S. (SVP - General Counsel) | Sale | 9,079 | 275.22 | 2,498,758 |
| 2020-07-09 | Furlow Brenda S. (SVP - General Counsel) | Option Ex | 9,079 | 108.49 | 984,980 |
| 2020-07-07 | Hippel James (Chief Financial Officer) | Sale | 2,577 | 271.41 | 699,413 |
| 2020-07-07 | Hippel James (Chief Financial Officer) | Option Ex | 2,577 | 108.49 | 279,578 |
| 2020-07-06 | Hippel James (Chief Financial Officer) | Sale | 21,502 | 272.51 | 5,859,531 |
| 2020-07-06 | Hippel James (Chief Financial Officer) | Option Ex | 21,502 | 108.49 | 2,332,751 |
Insider trading activities including stock purchases, stock sales, and option exercises of TECH listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Bio-techne Corp (symbol TECH, CIK number 842023) see the Securities and Exchange Commission (SEC) website.